RU2011109078A - Лечение легочной артериальной гипертензии - Google Patents
Лечение легочной артериальной гипертензии Download PDFInfo
- Publication number
- RU2011109078A RU2011109078A RU2011109078/04A RU2011109078A RU2011109078A RU 2011109078 A RU2011109078 A RU 2011109078A RU 2011109078/04 A RU2011109078/04 A RU 2011109078/04A RU 2011109078 A RU2011109078 A RU 2011109078A RU 2011109078 A RU2011109078 A RU 2011109078A
- Authority
- RU
- Russia
- Prior art keywords
- ness
- alkyl
- group
- mono
- zero
- Prior art date
Links
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 title claims 13
- 125000000217 alkyl group Chemical group 0.000 claims abstract 53
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 15
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract 14
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 14
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 12
- -1 benzcycloalkyl Chemical group 0.000 claims abstract 11
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 11
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 11
- 239000001257 hydrogen Substances 0.000 claims abstract 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 11
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract 11
- 125000003277 amino group Chemical group 0.000 claims abstract 10
- 125000004423 acyloxy group Chemical group 0.000 claims abstract 8
- 125000002619 bicyclic group Chemical group 0.000 claims abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 8
- 125000002950 monocyclic group Chemical group 0.000 claims abstract 8
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 8
- 125000004434 sulfur atom Chemical group 0.000 claims abstract 8
- 125000000714 pyrimidinyl group Chemical class 0.000 claims abstract 7
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims abstract 4
- 125000002947 alkylene group Chemical group 0.000 claims abstract 4
- 125000003118 aryl group Chemical group 0.000 claims abstract 4
- 125000005842 heteroatom Chemical group 0.000 claims abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000003373 pyrazinyl group Chemical group 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000006413 ring segment Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 101100437773 Homo sapiens BMPR2 gene Proteins 0.000 claims 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 1
- 229940127293 prostanoid Drugs 0.000 claims 1
- 150000003814 prostanoids Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8838208P | 2008-08-13 | 2008-08-13 | |
| US61/088,382 | 2008-08-13 | ||
| US16450109P | 2009-03-30 | 2009-03-30 | |
| US61/164,501 | 2009-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011109078A true RU2011109078A (ru) | 2012-09-20 |
Family
ID=41137217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011109078/04A RU2011109078A (ru) | 2008-08-13 | 2009-08-11 | Лечение легочной артериальной гипертензии |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20110190313A1 (OSRAM) |
| EP (1) | EP2315592A1 (OSRAM) |
| JP (1) | JP2011530607A (OSRAM) |
| KR (1) | KR20110053354A (OSRAM) |
| CN (1) | CN102123711A (OSRAM) |
| AU (1) | AU2009282104A1 (OSRAM) |
| BR (1) | BRPI0917491A2 (OSRAM) |
| CA (1) | CA2732789A1 (OSRAM) |
| CL (1) | CL2011000295A1 (OSRAM) |
| IL (1) | IL210922A0 (OSRAM) |
| MA (1) | MA32617B1 (OSRAM) |
| MX (1) | MX2011001668A (OSRAM) |
| NZ (1) | NZ590839A (OSRAM) |
| RU (1) | RU2011109078A (OSRAM) |
| TW (1) | TW201010999A (OSRAM) |
| WO (1) | WO2010019540A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011010865A (ja) | 2009-06-30 | 2011-01-20 | Ikaria Holdings Inc | 肺高血圧の臨床的または超音波心臓検査上の証拠を伴う低酸素性呼吸器不全に罹った満期産およびほぼ満期産の新生児を治療する方法 |
| DK3007689T3 (en) | 2013-01-10 | 2018-06-14 | Pulmokine Inc | NON-SELECTIVE KINASE INHIBITORS |
| AU2014296032A1 (en) * | 2013-07-31 | 2016-03-17 | Windward Pharma, Inc. | Aerosol tyrosine kinase inhibitor compounds and uses thereof |
| JP6483714B2 (ja) | 2013-10-11 | 2019-03-13 | ローレンス エス． ジスマン， | 噴霧乾燥製剤 |
| JP2020500183A (ja) | 2016-10-27 | 2020-01-09 | プルモキネ、インコーポレイテッド | 肺高血圧症の治療のための併用療法 |
| KR102486434B1 (ko) | 2016-11-08 | 2023-01-09 | 리아타 파마슈티컬즈 홀딩스, 엘엘씨 | 바독솔론 메틸 또는 이의 유사체를 사용하는 알포트 증후군의 치료 방법 |
| WO2019157337A1 (en) * | 2018-02-08 | 2019-08-15 | Pulmokine, Inc. | Formulations of kinase inhibitors and prostanoids |
| US11464776B2 (en) | 2019-05-16 | 2022-10-11 | Aerovate Therapeutics, Inc. | Inhalable imatinib formulations, manufacture, and uses thereof |
| AU2020274521A1 (en) | 2019-05-16 | 2021-12-16 | Aerovate Therapeutics, Inc. | Imatinib formulations, manufacture, and uses thereof |
| US20210154193A1 (en) * | 2019-11-25 | 2021-05-27 | PHPrecisionMed, LLC | Pharmaceutical compositions for the treatment of pulmonary hypertension |
| WO2022056196A1 (en) * | 2020-09-11 | 2022-03-17 | Pulmosim Therapeutics Llc | Compositions and methods for treating or preventing pulmonary hypertension |
| WO2022108939A1 (en) | 2020-11-17 | 2022-05-27 | United Therapeutics Corporation | Inhaled imatinib for pulmonary hypertension field |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| US20060154936A1 (en) * | 2002-10-25 | 2006-07-13 | Lasky Joseph A | Use of n-'5-'4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension |
| GB0325031D0 (en) * | 2003-10-27 | 2003-12-03 | Novartis Ag | Organic compounds |
| MX2007009135A (es) * | 2005-01-28 | 2007-09-06 | Novartis Ag | Uso de pirimidilaminobenzamidas para el tratamiento de enfermedades que responden a la modulacion de la actividad de la cinasa tie-2. |
| KR20080004564A (ko) * | 2005-05-02 | 2008-01-09 | 노파르티스 아게 | 과호산구성 증후군을 위한 피리미딜아미노벤즈아미드유도체 |
| AU2006323992B2 (en) * | 2005-12-06 | 2010-07-08 | Novartis Ag | Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis |
| CA2668190A1 (en) * | 2006-11-03 | 2008-05-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
-
2009
- 2009-08-11 EP EP09791358A patent/EP2315592A1/en not_active Withdrawn
- 2009-08-11 RU RU2011109078/04A patent/RU2011109078A/ru not_active Application Discontinuation
- 2009-08-11 CN CN2009801314677A patent/CN102123711A/zh active Pending
- 2009-08-11 MX MX2011001668A patent/MX2011001668A/es not_active Application Discontinuation
- 2009-08-11 NZ NZ590839A patent/NZ590839A/xx not_active IP Right Cessation
- 2009-08-11 BR BRPI0917491A patent/BRPI0917491A2/pt not_active IP Right Cessation
- 2009-08-11 WO PCT/US2009/053358 patent/WO2010019540A1/en not_active Ceased
- 2009-08-11 CA CA2732789A patent/CA2732789A1/en not_active Abandoned
- 2009-08-11 US US13/058,742 patent/US20110190313A1/en not_active Abandoned
- 2009-08-11 AU AU2009282104A patent/AU2009282104A1/en not_active Abandoned
- 2009-08-11 JP JP2011523078A patent/JP2011530607A/ja active Pending
- 2009-08-11 KR KR1020117005744A patent/KR20110053354A/ko not_active Withdrawn
- 2009-08-12 TW TW098127172A patent/TW201010999A/zh unknown
-
2011
- 2011-01-27 IL IL210922A patent/IL210922A0/en unknown
- 2011-02-11 CL CL2011000295A patent/CL2011000295A1/es unknown
- 2011-03-07 MA MA33678A patent/MA32617B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ590839A (en) | 2013-02-22 |
| EP2315592A1 (en) | 2011-05-04 |
| MA32617B1 (fr) | 2011-09-01 |
| KR20110053354A (ko) | 2011-05-20 |
| WO2010019540A1 (en) | 2010-02-18 |
| CL2011000295A1 (es) | 2011-07-15 |
| CA2732789A1 (en) | 2010-02-18 |
| JP2011530607A (ja) | 2011-12-22 |
| CN102123711A (zh) | 2011-07-13 |
| AU2009282104A1 (en) | 2010-02-18 |
| US20110190313A1 (en) | 2011-08-04 |
| BRPI0917491A2 (pt) | 2015-12-01 |
| TW201010999A (en) | 2010-03-16 |
| IL210922A0 (en) | 2011-04-28 |
| MX2011001668A (es) | 2011-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011109078A (ru) | Лечение легочной артериальной гипертензии | |
| JP2011530607A5 (OSRAM) | ||
| EP3028702B1 (en) | Methods of treatment using selective bcl-2 inhibitors | |
| PE20241707A1 (es) | Composicion farmaceutica que comprende un compuesto de quinazolina | |
| RU2011137399A (ru) | Гетероциклическое производное | |
| RU2012124811A (ru) | СПОСОБ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И ДРУГИХ ПАТОЛОГИЧЕСКИХ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ АКТИВНОСТЬЮ КИНАЗ Bcr-Abl, c-Kit, DDR1, DDR2, ИЛИ PDGF-R | |
| JP2018502877A5 (OSRAM) | ||
| RU2017145026A (ru) | Соединение, ингибирующее brk | |
| JOP20200042A1 (ar) | مشتقات 3-(1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6-دايون واستخداماتها | |
| RU2012147511A (ru) | Применение ингибиторов c-src в комбинации с пиримидиламинобензамидом для лечения лейкоза | |
| CA3094449A1 (en) | Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases | |
| RU2007108861A (ru) | Трифтометилзамещенные бензамиды в качестве ингибиторов киназ | |
| AR077468A1 (es) | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa | |
| RU2003114752A (ru) | Лечение желудочно-кишечных стромальных опухолей | |
| RU2004132844A (ru) | Производные бензамида, полехные в качестве ингибиторов деацетилазы гистонов | |
| RU2014136339A (ru) | Замещенные пролины/пиперидины как антагонисты орексиновых рецепторов | |
| RU2015106605A (ru) | Соединения замещенных пиразолонов и способы использования | |
| RU2012120901A (ru) | Способ лечения пролиферативных расстройств и других патологических состояний, опосредованных действием киназ bcr-abl, c-kit, ddr1, ddr2 или pdgf-r | |
| AR070220A1 (es) | Amino-bencimidazoles sustituidos medicamentos que comprenden dicho compuestos, uso y metodos de fabricacion de los mismos | |
| WO2020092618A9 (en) | Methods of treating depression, anxiety and sexual dysfunction using the compound pimavanserin | |
| RU2304436C2 (ru) | Применение производных n-фенил-2-пиримидинамина против основывающихся на мастоцитах заболеваний, подобных аллергическим нарушениям | |
| RU2014144951A (ru) | Новое 1-замещенное производное индазола | |
| AU2002307140A1 (en) | Use of N-Phenyl-2-Pyrimidineamine Derivatives against mast cell-based diseases like allergic disorders | |
| MY146403A (en) | F, g, h, i and k crystal forms of imatinib mesylate | |
| RU2008114048A (ru) | Комбинации, включающие ингибитор рецептора сэфр (сосудистого эндотелиального фактора роста) и агент, увеличивающий проницаемость |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20131007 |